Sensei Biotherapeutics (NASDAQ:FTH) Research Coverage Started at William Blair

William Blair initiated coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a report issued on Friday morning, Marketbeat Ratings reports. The firm issued an outperform rating on the stock.

Other research analysts also recently issued reports about the company. Wall Street Zen downgraded Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. Citizens Jmp began coverage on Sensei Biotherapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target on the stock. Oppenheimer initiated coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price target for the company. BTIG Research reissued a “buy” rating and issued a $55.00 price target on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Finally, TD Cowen started coverage on Sensei Biotherapeutics in a research report on Wednesday, September 9th. They set a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics has an average rating of “Moderate Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ:FTH opened at $18.80 on Friday. The firm has a market capitalization of $485.79 million, a price-to-earnings ratio of -0.13 and a beta of -0.29. The business’s fifty day simple moving average is $31.39. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping the consensus estimate of ($5.04) by $2.20. Research analysts anticipate that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in shares of Sensei Biotherapeutics during the second quarter worth $307,000. Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the last quarter. Bank of America Corp DE lifted its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the period. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics in the first quarter valued at $4,188,000. Finally, Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics in the second quarter valued at $3,610,000. 10.50% of the stock is owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.